|
Acquisitions (Details)
In Thousands, unless otherwise specified |
3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 15 Months Ended | 12 Months Ended | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
USD ($)
|
Sep. 30, 2011
USD ($)
|
Jun. 30, 2011
USD ($)
|
Mar. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Sep. 30, 2010
USD ($)
|
Jun. 30, 2010
USD ($)
|
Mar. 31, 2010
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2010
USD ($)
|
Dec. 31, 2009
USD ($)
|
Dec. 31, 2011
GOFA [Member]
USD ($)
|
Dec. 31, 2011
GOFA [Member]
EUR (€)
|
Dec. 31, 2011
Clever Fellows Innovation Consortium [Member]
USD ($)
|
Apr. 02, 2011
Clever Fellows Innovation Consortium [Member]
USD ($)
|
Dec. 31, 2011
SeQual Technologies, Inc. [Member]
USD ($)
|
Aug. 31, 2011
Cryotech International, Inc. [Member]
USD ($)
|
Dec. 31, 2011
Cryotech International, Inc. [Member]
USD ($)
|
Jun. 30, 2011
Covidien Japn Inc. - Liquid Oxygen Therapy Business [Member]
USD ($)
|
Dec. 31, 2010
Covidien Japn Inc. - Liquid Oxygen Therapy Business [Member]
USD ($)
|
Dec. 31, 2011
BioMedical [Member]
Clever Fellows Innovation Consortium [Member]
USD ($)
|
Dec. 31, 2011
BioMedical [Member]
SeQual Technologies, Inc. [Member]
USD ($)
|
Dec. 31, 2011
BioMedical [Member]
Cryotech International, Inc. [Member]
USD ($)
|
Dec. 31, 2011
Selling, General and Administrative Expense [Member]
Clever Fellows Innovation Consortium [Member]
USD ($)
|
Dec. 31, 2011
Selling, General and Administrative Expense [Member]
SeQual Technologies, Inc. [Member]
USD ($)
|
|
| Net assets acquired: | |||||||||||||||||||||||||
| Cash | $ 1,974 | $ 218 | |||||||||||||||||||||||
| Accounts receivable | 4,645 | 6,169 | |||||||||||||||||||||||
| Inventory | 8,382 | 4,959 | |||||||||||||||||||||||
| Property and equipment | 15,555 | 711 | |||||||||||||||||||||||
| Other assets | 118 | 184 | |||||||||||||||||||||||
| Intangible assets | 7,258 | 31,760 | |||||||||||||||||||||||
| Goodwill | 11,438 | 2,938 | 7,210 | 4,227 | |||||||||||||||||||||
| Liabilities assumed | (9,560) | (7,799) | |||||||||||||||||||||||
| Total purchase price | 39,810 | 43,412 | |||||||||||||||||||||||
| Business combination equity interest percentage | 100.00% | 100.00% | 100.00% | ||||||||||||||||||||||
| Acquisition of businesses, net of cash acquired | 37,680 | 47,865 | 18,086 | 26,261 | |||||||||||||||||||||
| Working capital adjustment | 947 | ||||||||||||||||||||||||
| Potential purchase price in cash | 5,000 | 60,000 | 6,653 | ||||||||||||||||||||||
| Cash paid for acquisition | 2,000 | 38,312 | 4,053 | 1,008 | |||||||||||||||||||||
| Sales | 219,635 | 211,311 | 200,698 | 162,941 | 158,838 | 139,205 | 139,144 | 118,268 | 794,585 | 555,455 | 597,458 | 840 | 35,081 | 11,928 | |||||||||||
| Duration of payments for contingent consideration | 3 years | 2 years | 2 years | ||||||||||||||||||||||
| Contingent consideration at acquisition | 1,857 | 1,650 | 4,369 | 841 | |||||||||||||||||||||
| Increase (decrease) in fair value of the contingent consideration | 341 | 207 | 731 | ||||||||||||||||||||||
| Fair value of net assets acquired | 28,372 | 732 | 1,626 | 2,132 | |||||||||||||||||||||
| Contingent consideration payment | 1,300 | ||||||||||||||||||||||||
| Gain on acquisition of business | 1,124 | 0 | 1,124 | 6,954 | 1,124 | ||||||||||||||||||||
| Net income | $ 8,316 | $ 17,505 | $ 11,020 | $ 7,403 | $ 9,963 | $ 6,665 | $ 2,458 | $ 1,419 | $ 44,244 | $ 20,505 | $ 61,156 | $ 572 | $ 842 | ||||||||||||